Quarterly ResultAug 6, 2026, 04:17 PM
Evommune Q2 Net Loss $(32.2)M; Raises $117.2M in Private Placement
AI Summary
Evommune, Inc. reported a net loss of $(32.2) million for the three months ended June 30, 2026, and $(53.9) million for the six months ended June 30, 2026. The clinical-stage biotechnology company increased its research and development expenses significantly year-over-year. In February 2026, the company successfully raised $117.2 million through a private placement of common stock, which is expected to fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q2 2026 was $(32.2) million, compared to $(13.6) million in Q2 2025.
- Net loss for H1 2026 was $(53.9) million, compared to $(28.1) million in H1 2025.
- Research and development expenses increased to $26.4 million in Q2 2026 from $19.6 million in Q2 2025.
- Raised $117.2 million net proceeds from a private placement of common stock in February 2026.
- Cash and cash equivalents were $60.0 million as of June 30, 2026.
- Total assets increased to $301.9 million as of June 30, 2026, from $224.9 million at year-end 2025.
- Management expects existing funds to cover operating plans for at least 12 months.
Price Impact
More from EVMN